Indications › Osteoarthritis
GLP‑1 drugs in osteoarthritis
Which incretin agents are being studied in osteoarthritis, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 10
- Active
- 4
- Results scheduled
- 3
- Molecules studied
- 5
- Sponsors
- 6
No GLP‑1 or incretin drug is FDA-approved for osteoarthritis. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.
No GLP-1 or incretin drug is approved for osteoarthritis, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 9 of the 10 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 1 still in early phases. 6 distinct sponsors are involved, 4 of the trials run commercially and the rest by universities and hospitals.
Molecules studied in this indication
ecnoglutide · liraglutide · orforglipron · retatrutide · tirzepatide
Results due in this indication
| Est. completion | Drug | Trial | Phase | Participants |
|---|---|---|---|---|
| 2027-05 | tirzepatide | Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA) NCT06191848 · University of Melbourne | P4 | 352 |
| 2028-04 | orforglipron | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee NCT07153471 · Eli Lilly and Company | P3 | 800 |
| 2028-05-31 | ecnoglutide | A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA) NCT07734311 · Hangzhou Sciwind Biosciences Co., Ltd. | P3 | 360 |
Trials on file
All 10 incretin trials recorded in this indication, active first.